摘要
目的:探讨消瘰丸(Ⅱ)对LPS诱导的附睾炎的影响机制。方法:使用LPS局部注射法构建附睾炎小鼠模型;研究分为生理盐水对照组(n=5)、模型组(n=5)、模型+消瘰丸组(n=5)和生理盐水+消瘰丸组(n=5);消瘰丸(Ⅱ)/生理盐水连续灌胃14 d后,检测附睾组织病理变化、NLRP3炎症小体和Caspase-1的表达以及相关蛋白水平。结果:与模型组相比,消瘰丸(Ⅱ)能显著减轻炎性细胞浸润和病变,降低NLRP3、Caspase-1、Cleaved-Caspase-1、IL-1β、IL-18、GSDMD、p-p38 MAPK蛋白表达水平(P<0.05或P<0.01),减少炎症反应。结论:消瘰丸(Ⅱ)通过调控NLRP3介导的细胞焦亡途径,减轻附睾炎症水平,改善小鼠附睾上皮损伤。
Objective:This study aimed to investigate the mechanism of Xiaoluanwan(Ⅱ)in treating lipopolysaccharide(LPS)-induced epididymitis and its impact on the NLRP3 inflammasome.Methods:The murine epididymitis model was established through local injection of LPS.The study included a control group(n=5),a model group(n=5),a model group treated with Xiaoluanwan(Ⅱ)(Ⅱ)(n=5),and a saline group treated with Xiaoluanwan(Ⅱ)(n=5).After 14 consecutive days of oral administration of Xiaoluanwan(Ⅱ)or physiological saline,pathological changes in the epididymal tissues,expression levels of NLRP3 inflammasome and Caspase-1,as well as associated protein levels were examined.Results:Compared to the model group,Xiaoluanwan(Ⅱ)significantly alleviated inflammatory cell infiltration and lesions,as evidenced by a reduction in the protein expression levels of NLRP3,Caspase-1,Cleaved-Caspase-1,IL-1β,IL-18,GSDMD,and p-p38 MAPK(P<0.05,0.01,0.05,0.05,0.001,0.01,0.05),thereby mitigating the inflammatory response.Conclusion:Xiaoluanwan(Ⅱ)alleviates epididymal inflammation and ameliorates mouse epididymal epithelial injury by modulating the NLRP3-mediated cell pyroptosis pathway.
作者
战明威
刘朋飞
周玉春
余怡
赖雨琪
王磊
詹绪新
娄强
吴科荣
商学军
ZHAN Ming-wei;LIU Peng-fei;ZHOU Yu-chun;YU Yi;LAI Yu-qi;WANG Lei;ZHAN Xu-xin;LOU Qiang;WU Ke-rong;SHANG Xue-jun(Department of Urology,Jinling Hospital Affiliated to Nanjing University School of Medicine/General Hospital of Eastern Theater Command,Nanjing,Jiangsu 210002,China;Department of Andrology,Affiliated Hospital of Nanjing University of Chinese Medicine,Nanjing,Jiangsu 210022,China;Department of Urology/Center of Reproductive Medicine,The First Affiliated Hospital of Ningbo University,Ningbo,Zhejang 315100 China;Nanjing University of Chinese Medicine,Nanjing,Jiangsu 210023,China;School of Medicine,Southeast University,Nanjing,Jiangsu 210009,China;Reproductive Medicine Center,The People's Hospital of Xi'an(Fourth Hospital of Xi'an),Xi'an,Shanxi 710004,China;Department of Urology,Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine,Guiyang,Guizhou 550001,China)
出处
《中华男科学杂志》
CAS
CSCD
北大核心
2023年第6期483-489,共7页
National Journal of Andrology
基金
宁波市泌尿系统疾病临床医学研究中心(2019A21001)
